These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 10367337)

  • 21. Metabolomic profiles of arsenic (+3 oxidation state) methyltransferase knockout mice: effect of sex and arsenic exposure.
    Huang MC; Douillet C; Su M; Zhou K; Wu T; Chen W; Galanko JA; Drobná Z; Saunders RJ; Martin E; Fry RC; Jia W; Stýblo M
    Arch Toxicol; 2017 Jan; 91(1):189-202. PubMed ID: 26883664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of arsenic exposure on DNA methylation and epigenetic gene regulation.
    Reichard JF; Puga A
    Epigenomics; 2010 Feb; 2(1):87-104. PubMed ID: 20514360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concentration-dependent cellular responses of arsenic in keratinocytes.
    Liao WT; Lan CC; Lee CH; Yu HS
    Kaohsiung J Med Sci; 2011 Sep; 27(9):390-5. PubMed ID: 21914526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Arsenic, mode of action at biologically plausible low doses: what are the implications for low dose cancer risk?
    Snow ET; Sykora P; Durham TR; Klein CB
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):557-64. PubMed ID: 15996700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arsenic and cancer: Evidence and mechanisms.
    Speer RM; Zhou X; Volk LB; Liu KJ; Hudson LG
    Adv Pharmacol; 2023; 96():151-202. PubMed ID: 36858772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arsenic (+3 oxidation state) methyltransferase and the inorganic arsenic methylation phenotype.
    Li J; Waters SB; Drobna Z; Devesa V; Styblo M; Thomas DJ
    Toxicol Appl Pharmacol; 2005 Apr; 204(2):164-9. PubMed ID: 15808521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report.
    Clewell HJ; Thomas RS; Gentry PR; Crump KS; Kenyon EM; El-Masri HA; Yager JW
    Toxicol Appl Pharmacol; 2007 Aug; 222(3):388-98. PubMed ID: 17499324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In utero arsenic exposure in mice and early life susceptibility to cancer.
    Garry MR; Santamaria AB; Williams AL; DeSesso JM
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):378-90. PubMed ID: 26239692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low doses of arsenic, via perturbing p53, promotes tumorigenesis.
    Ganapathy S; Li P; Fagman J; Yu T; Lafontant J; Zhang G; Chen C
    Toxicol Appl Pharmacol; 2016 Sep; 306():98-104. PubMed ID: 27425828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Advance on oxidative stress mechanism of arsenic toxicology].
    Li Z; An Y
    Wei Sheng Yan Jiu; 2009 Sep; 38(5):634-6, 640. PubMed ID: 19877531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of arsenic carcinogenesis: an integrated approach.
    Rossman TG
    Mutat Res; 2003 Dec; 533(1-2):37-65. PubMed ID: 14643412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genotoxic and epigenetic mechanisms in arsenic carcinogenicity.
    Bustaffa E; Stoccoro A; Bianchi F; Migliore L
    Arch Toxicol; 2014 May; 88(5):1043-67. PubMed ID: 24691704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elucidating the pathway for arsenic methylation.
    Thomas DJ; Waters SB; Styblo M
    Toxicol Appl Pharmacol; 2004 Aug; 198(3):319-26. PubMed ID: 15276411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of differentially expressed genes in the livers of chronically i-As-treated hamsters.
    Hernández A; Sampayo-Reyes A; Marcos R
    Mutat Res; 2011 Aug; 713(1-2):48-55. PubMed ID: 21658394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arsenic-Induced Carcinogenesis: The Impact of miRNA Dysregulation.
    Cardoso APF; Al-Eryani L; States JC
    Toxicol Sci; 2018 Oct; 165(2):284-290. PubMed ID: 29846715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The interaction of arsenic and N-butyl-N-(4-hydroxybutyl)nitrosamine on urothelial carcinogenesis in mice.
    Dai YC; Wang SC; Haque MM; Lin WH; Lin LC; Chen CH; Liu YW
    PLoS One; 2017; 12(10):e0186214. PubMed ID: 29016672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current progress in animal models of arsenic carcinogenesis].
    An Y
    Wei Sheng Yan Jiu; 2006 Nov; 35(6):814-8. PubMed ID: 17290776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epimutagenesis: A prospective mechanism to remediate arsenic-induced toxicity.
    Paul S; Giri AK
    Environ Int; 2015 Aug; 81():8-17. PubMed ID: 25898228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implications of arsenic genotoxicity for dose response of carcinogenic effects.
    Rudel R; Slayton TM; Beck BD
    Regul Toxicol Pharmacol; 1996 Apr; 23(2):87-105. PubMed ID: 8661328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular mechanisms of arsenic carcinogenesis.
    Huang C; Ke Q; Costa M; Shi X
    Mol Cell Biochem; 2004 Jan; 255(1-2):57-66. PubMed ID: 14971646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.